Regimen Name: CE Origin of Name: CE is an acronym for the 2 medications in the regimen: carboplatin and etoposide.
COMMENTS
Carboplatin doses are commonly calculated using equations based on the method of Calvert et al. 1 Calvert's group showed that the carboplatin dose in milligrams can be calculated using a selected carboplatin area under the curve (AUC) and the patient's glomerular filtration rate (GFR) as determined by clearance of a radiopharmaceutical, chromium-51-EDTA. Calvert's equation is expressed as carboplatin dose mg 5 AUC x [GFR 1 25] . A common practice is to substitute the GFR of the Calvert equation with a calculated creatinine clearance (CrCl) determined with the Cockcroft-Gault equation.
INDICATION(S)
The CE regimen has been studied and is recommended for primary treatment of both limited and extensive-stage small-cell lung cancer (SCLC) ( Table 1) . [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing carboplatin and etoposide. A. Carboplatin 1. Use carboplatin injection 10 mg/mL, or powder for reconstitution. 2. Reconstitute the powder to a concentration of 10 mg/mL with sterile water for injection (SWFI), 5% dextrose in water (D5W), or 0.9% sodium chloride (NS). 3. Dilute with 100 to 1,000 mL of D5W or NS. 4. Carboplatin is less stable in saline solutions, with up to 5% degradation within 24 hours. 13 
SUPPORTIVE CARE
A. Acute and Delayed Emesis Prophylaxis: The CE regimen is predicted to cause acute emesis in 30% to 90% of patients. 14 The studies reviewed reported grade 3 nausea or vomiting in 0.2% to 9% of patients. 2, 3, [5] [6] [7] 9, 10 Appropriate acute emesis prophylaxis includes a serotonin antagonist and a corticosteroid plus or minus a neurokinin antagonist in selected patients. [15] [16] [17] [18] One of the following regimens is suggested: The antiemetic therapy should continue for at least 2 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid or a steroid and dopamine antagonist combination most appropriate for follow-up therapy. 19 One of the following regimens is suggested:
1. guidelines and pharmaco-economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 21, 22 Since febrile neutropenia (grade 3 or 4) was reported in 3% to 14% of patients in the trials of CE, primary prophylactic use of CSFs may be considered if the patient has had febrile neutropenia or grade 4 neutropenia in a prior cycle of CE or has other known risk factors for febrile neutropenia. 21, 22 
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Unspecified cardiac events (grade 4) 6%. 10 B. Dermatologic: Alopecia (all grades) 34%, 2 (grade 3) 10%, 11 7 c. Greater than 3,500 cells/mcL. 9 d. Greater than 3,000 cells/mcL. 11 2. Absolute neutrophil count (ANC): a. Greater than 2,000 cells/mcL. 4, 11 b. Greater than 1,500 cells/mcL. 10 
Platelet count:
a. Greater than or equal to 100,000 cells/ mcL. [3] [4] [5] [6] [8] [9] [10] [11] b. Greater than 150,000 cells/mcL. 7 
Serum creatinine:
a. Less than or equal to 1.5 mg/dL. 3, 11 b. Less than 1.4 mg/dL. 4 c. Less than 1.25 times upper limit of normal (ULN). 5,6 d. Less than 2 times ULN. 7 5. Blood urea nitrogen (BUN) and serum creatinine: a. Less than 2 times ULN. 8 b. Less than or equal to 1.5 times ULN. 11 6. CrCl: a. Greater than or equal to 50 mL/min. 3 b. Greater than or equal to 30 mL/min. 8 c. Greater than 60 mL/min. 9 d. Greater than 20 mL/min. 10 7. Serum bilirubin: a. Less than or equal to 1.5 mg/dL. 3, 8, 11 b. Less than 1.25 times ULN. 5,6 8. Hemoglobin: a. Greater than or equal to 9 g/dL. 3, 6, 8 b. Greater than 10 g/dL. 9,11 9. AST/ALT: a. Less than or equal to 2 times ULN. 3, 8 b. AST less than or equal to 2.5 times ULN or less than or equal to 5 times ULN if liver metastases present. 11 In clinical practice, a pretreatment absolute neutrophil count (ANC) of 1,000 cells/mcL and platelets of 75,000 cells/mcL are usually considered acceptable. 
DOSAGE MODIFICATIONS

